“Catalent and SELLAS Sign Exclusive Agreement for Therapeutic Reprofiling of Zolpidem”
The OptiDose technology is innovative and versatile for unique differentiated controlled
release and combination dose forms.
Allows for high-dose zolpidem administration as monotherapy or combination therapy with
unique immediate- and slow release formulation.
This proprietary technology and formulation further compliments and strengthens current IP
and inclusion of REMS program.
For more information press here